

Lars BÃ,

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1761046/publications.pdf>

Version: 2024-02-01

17
papers

589
citations

687363

13
h-index

888059

17
g-index

17
all docs

17
docs citations

17
times ranked

1062
citing authors

#	ARTICLE	IF	CITATIONS
1	Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 621-625.	1.9	180
2	Employment among Patients with Multiple Sclerosis-A Population Study. <i>PLoS ONE</i> , 2014, 9, e103317.	2.5	77
3	B cell depletion in the treatment of multiple sclerosis. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 261-271.	3.1	50
4	Deep Gray Matter Demyelination Detected by Magnetization Transfer Ratio in the Cuprizone Model. <i>PLoS ONE</i> , 2013, 8, e84162.	2.5	48
5	The cuprizone model: regional heterogeneity of pathology. <i>Apmis</i> , 2012, 120, 648-657.	2.0	36
6	Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis. <i>BMC Research Notes</i> , 2019, 12, 497.	1.4	35
7	Magnetization transfer ratio does not correlate to myelin content in the brain in the MOG-EAE mouse model. <i>Neurochemistry International</i> , 2015, 83-84, 28-40.	3.8	28
8	Fingolimod does not enhance cerebellar remyelination in the cuprizone model. <i>Journal of Neuroimmunology</i> , 2015, 285, 180-186.	2.3	22
9	Relationship Between White Matter Lesions and Gray Matter Atrophy in Multiple Sclerosis. <i>Neurology</i> , 2022, 98, .	1.1	21
10	Fingolimod downregulates brain sphingosine-1-phosphate receptor 1 levels but does not promote remyelination or neuroprotection in the cuprizone model. <i>Journal of Neuroimmunology</i> , 2020, 339, 577091.	2.3	18
11	Cuprizone and EAE mouse frontal cortex proteomics revealed proteins altered in multiple sclerosis. <i>Scientific Reports</i> , 2021, 11, 7174.	3.3	17
12	Botulinum Toxin as Monotherapy in Symptomatic Trigeminal Neuralgia. <i>Headache</i> , 2016, 56, 1035-1039.	3.9	16
13	Safety and efficacy of autologous hematopoietic stem cell transplantation for multiple sclerosis in Norway. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1889-1897.	3.0	14
14	Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHST. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 844-848.	1.9	11
15	Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis â€œ A cohort study. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732097304.	1.0	10
16	The effect of gadolinium-based contrast-agents on automated brain atrophy measurements by FreeSurfer in patients with multiple sclerosis. <i>European Radiology</i> , 2022, 32, 3576-3587.	4.5	4
17	A higher proportion of ermin-immunopositive oligodendrocytes in areas of remyelination. <i>PLoS ONE</i> , 2021, 16, e0256155.	2.5	2